CoChat

Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program

Peng, Hui, Want, Laura L., Aroda, Vanita R. · 2016 · Current Diabetes Reports

The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated benefits for patients with type 2 diabetes including A1C reduction and weight loss with minimal risk of hypoglycemia. This article provides an evidence-based update of safety and tolerability considerations for the clinical use of GLP-1RAs as a class, with a specific detailed review of data from the exenatide clinical trial development program, which has the longest history and availability of safety and tolerability data as the first-approved GLP-1RA. Specific areas covered include comparative risk of hypoglycemia, as well as pancreatic, thyroid, and cardiovascular safety data; clinical guidance regarding current safety and tolerability data is also reviewed.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11892-016-0728-4

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 87 references

Research works printed but not linked: 3

  1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2015;38 Suppl 1:S1–93.
  2. Riddle M, Ahmann A, Basu A, Aroda V, Ratner R. Metformin+exenatide+basal insulin vs metformin+placebo+basal insulin: reaching A1c <6.5% without weight-gain or serious hypoglycemia (abstract). Diabetes. 2010;59(Suppl 1A):LB6.
  3. Chilton RJ, MacConell LA, Han J, Marso SP. Characterization of heart rate increases with glucagon-like peptide-1 agonist therapy (abstract). Circulation. 2013;128:A16290.

Cited by

See all 21

Metadata

Authors
Peng, H., Want, L. L., & Aroda, V. R.
Affiliations
  • MedStar Washington Hospital Center (US)
  • MedStar Health Research Institute (US)
  • Georgetown University (US)
Corresponding author
Aroda, Vanita R.
Venue
Current Diabetes Reports
Published
2016-04-01
Volume
16
Issue
5
Pages
44-44
ISSN
  • 1534-4827 (ISSN-L)
  • 1539-0829
OpenAlex
W2332435010
Cited by
20
References
88
Citations by year
2026: 1 · 2023: 2 · 2022: 4 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 5 · 2016: 4
FWCI
0.54
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Current Diabetes Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, exenatide, type 2 diabetes, drug safety, tolerability, hypoglycemia risk, cardiovascular safety
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Animals, Antibodies, Antibody Formation, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypoglycemia, Hypoglycemic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. https://app.cochat.ai/papers/10.1007/s11892-016-0728-4
The paper
Peng, H., Want, L. L., & Aroda, V. R. (2016). Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. Current Diabetes Reports. https://doi.org/10.1007/s11892-016-0728-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.